The Executive Passport for Pharmaceuticals and Life Sciences

The evidence chain is the enterprise

A molecule, device or platform creates different C-suite mandates as it moves from research uncertainty to regulated use

Life-sciences titles conceal development stage, modality, indication, regulatory path, trial responsibility, manufacturing model, quality system, evidence maturity, launch condition and capital horizon. A leader proven in commercial scale may not have governed pre-readout survival. A research-stage executive may never have reconciled validated supply, market access and public-company disclosure.

The Mandate Charter fixes entities, assets and programmes, development and commercial stage, patient and data perimeter, quality and regulatory interfaces, manufacturing and supplier model, capital runway, board and committee rights, first consequential decision and evidence exclusions. Candidate assessment asks who authored the decision while scientific, medical, quality and regulatory judgment remained with qualified owners.

Participant data, clinical outcomes, unblinded information, patient records, proprietary models, formulations, manufacturing secrets, protected regulatory correspondence and inside information do not enter the Passport. De-identified decision structure and consented observers can establish leadership evidence without exposing the asset.

Six offices around one programme

The board needs enterprise, finance, operations, workforce, technology and market truth before a programme result chooses the strategy for it

The CEO allocates enterprise attention and capital under scientific uncertainty. The CFO protects runway, reporting, collaboration economics and evidence behind forecasts. The COO makes development, quality, supply and launch dependencies executable. The CHRO builds scarce capability, incentives and succession without corrupting challenge. The CTO governs regulated and business records, data integrity, platforms and resilience. The CMO aligns evidence, access, compliant communication and launch readiness.

The thirty Search reviews require provider teams to distinguish these source populations and test transfer. The thirty Jobs dossiers help sitting executives identify which protected records can never support a public application and which bounded decisions can be corroborated privately.

Leader-side dossiers

Pharma and life-sciences mandate dossiers from research through commercial scale

Board-side provider reviews

Life-sciences executive-search provider reviews across five markets

Choose stage before prestige

Select the role and market whose programme condition matches the board's first decision

No page converts a trial, approval, financing, partnership or facility announcement into a vacancy. The company retains scientific, medical, quality, regulatory, privacy, IP, identity and reference diligence.

Review Gladwin's life-sciences practice

Inspect a mandate definition

Review bounded evidence